meRfi®-GM
Acute graft-versus-host disease (acute GVHD)
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Acute graft-versus-host disease (aGVHD) remains a major limitation of allogeneic stem cell transplantation (SCT), and severe intestinal manifestation is the major cause of early mortality
During the first step, which is associated with tissue damage, pro-inflammatory cytokines, such as tumor necrosis factor-alfa (TNF-alfa) or interleukin-1, are released.
After the Acute…
References (Sources)
- 2013 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): Current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders
- Acute graft versus host disease: Pathophysiology, risk factors, and prevention strategies
- Fecal Microbiota Transplantation for Treatment of Acute Graft-versus-Host Disease
- Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT
- Host-Specific Interleukin-2–Secreting Donor T-Cell Precursors as Predictors of Acute Graft-versus-Host Disease in Bone Marrow Transplantation between HLA-Identical Siblings
- Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity
- Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: An EBMT mega-file study